Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK.
Pratap
P
Neelakantan
Katayoun
K
Rezvani
Philippa
P
May
Gareth
G
Gerrard
Bua
B
Marco
Christos
C
Paliompeis
Alistair
A
Reid
John
J
Goldman
David
D
Marin
Dragana
D
Milojkovic
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate
chronic myeloid leukaemia; imatinib; side-effect; therapy change; tyrosine kinases